Intended for healthcare professionals

  1. Research
  2. Systematic review and...
  3. Systematic review and meta-analysis of randomised controlled trials of gastro-oesophageal reflux interventions for chronic cough associated with gastro-oesophageal reflux
Research

Systematic review and meta-analysis of randomised controlled trials of gastro-oesophageal reflux interventions for chronic cough associated with gastro-oesophageal reflux

BMJ 2006; 332 doi: https://doi.org/10.1136/bmj.38677.559005.55 (Published 05 January 2006) Cite this as: BMJ 2006;332:11
  1. A B Chang, consultant in paediatric respiratory medicine (annechang{at}ausdoctors.net)1,
  2. T J Lasserson, review group coordinator2,
  3. T O Kiljander, consultant in respiratory medicine3,
  4. F L Connor, consultant in paediatric gastroenterology4,
  5. J T Gaffney, research nurse1,
  6. L A Garske, consultant in respiratory medicine5
  1. 1 Department of Respiratory Medicine, Royal Children's Hospital, Herston, Brisbane, Qld 4029, Australia
  2. 2 Cochrane Airways Group, St George's Hospital Medical School, London SW17 0RE
  3. 3 Medical Center Mehiläinen, Kauppiaskatu 8, FIN-20100 Turku, Finland
  4. 4 Department of Gastroenterology, Royal Children's Hospital, Herston, Brisbane
  5. 5 Princess Alexandra Hospital, Brisbane, Woolloongabba, Qld 4102, Australia
  1. Correspondence to: A Chang
  • Accepted 27 October 2005

Abstract

Objective To evaluate the efficacy of treatment for gastro-oesophageal reflux disease (GORD) on chronic cough in children and adults without an underlying respiratory disease.

Design Systematic review and meta-analysis.

Data sources Cochrane, Medline, and Embase databases, references from review articles.

Included studies Randomised controlled trials on GORD treatment for cough in children and adults without primary lung disease. Two reviewers independently selected studies and extracted paediatric and adult data on primary (clinical failure) and secondary outcomes.

Results 11 studies were included. Meta-analysis was limited to five studies in adults that compared proton pump inhibitors with placebo. All outcomes favoured proton pump inhibitors: the odds ratio for clinical failure (primary outcome) was 0.24 (95% confidence interval 0.04 to 1.27); number needed to treat (NNT) was 5 (harm 50 to ∞ to benefit 2.5). For secondary outcomes, the standardised mean difference between proton pump inhibitors and placebo was −0.51 (−1.02 to 0.01) for mean cough score at the end of the trial and −0.29 (−0.62 to 0.04) for change in cough score at the end of the trial. Subgroup analysis with generic inverse variance analysis showed a significant mean change in cough (−0.41 SD units, −0.75 to −0.07).

Conclusion Use of a proton pump inhibitor to treat cough associated with GORD has some effect in some adults. The effect, however, is less universal than suggested in consensus guidelines on chronic cough and its magnitude of effect is uncertain.

Footnotes

  • Funding ABC is supported by the Australian National Health and Medical Research Council and the Royal Children's Hospital Foundation. This review was supported by a bursary from the Cochrane Child Health Field.

  • Competing interests ABC has received a small grant from Glaxo for a study on asthma. TOK has received lecturing fees from AstraZeneca, Wyeth, Pfizer, and Boehringer Ingelheim, and is a consultant for AstraZeneca. LAG has received lecturing fees from AstraZeneca.

  • Ethical approval Not required.

View Full Text
Back to top